
Videos





Classical Hodgkin Lymphoma: Is There a Cure?





Unresectable HCC with a History of Hepatitis C Virus






Chronic Lymphocytic Leukemia

Stephan Grupp, MD, PhD, discusses updated findings from the phase II ELIANA trial of tisagenlecleucel (Kymriah), a chimeric antigen receptor T-cell therapy, in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high disease burden.

Jordan Gauthier, MD, MSc, discusses the rationale for combining ibrutinib with CD19-targeting chimeric antigen receptor T cells for the treatment of patients with chronic lymphocytic leukemia.

David M. Siegel, MD, PhD, discusses one of the biggest dilemmas to arise recently in the treatment of multiple myeloma.







Relapsed Chronic Lymphocytic Leukemia




Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Fast Track Designation to Givastomig for Frontline HER2-Negative Metastatic Gastric Cancer
2
Real-World Cilta-Cel Outcomes Extend Beyond Trial Populations in R/R Myeloma
3
FDA Accepts BLA for Ozekibart in Unresectable or Metastatic Chondrosarcoma
4
Talquetamab Plus Daratumumab Improves PFS vs SOC in R/R Multiple Myeloma
5
